trending Market Intelligence /marketintelligence/en/news-insights/trending/le2cmznpafsvuugzwd86hw2 content esgSubNav
In This List

Kitov Pharma agrees to settle securities lawsuits for $2M

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Kitov Pharma agrees to settle securities lawsuits for $2M

Kitov Pharma Ltd. said it entered a settlement agreement regarding three shareholder class action lawsuits filed against the company.

The classes in all the lawsuits, which alleged violations of U.S. federal securities laws, will receive $2 million under the proposed settlement. The Israeli biopharmaceutical company expects its insurers to fund the settlement consideration, plus related expenses.

One lawsuit was filed in the District Court for the Southern District of New York while two were filed in the Superior Court for the State of California.

Under the proposed settlement, which will have no impact on the company's statement of operations, Kitov will not admit any wrongdoing or violation of federal or state securities laws.

The proposal is subject to certain conditions, including court approval.